ArticleGut and liver2026
Association between Type 2 Diabetes and Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in South Korea.
Article in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diabetes Duration, Severity, and the Risk of Gastrointestinal Bleeding: What the Gut Tells Us about Glucose.Gut and liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Type 2 diabetes mellitus (T2DM) is linked to an elevated risk of gastrointestinal bleeding (GIB), but the effects of diabetes duration and severity remain unclear. We investigated these associations in a nationwide Korean cohort. Methods: This retrospective cohort study used the Korean National Health Insurance database from individuals who underwent national health screening between 2009 and 2015. Participants were classified as having normal glucose, impaired fasting glucose (IFG), new-onset diabetes, diabetes <5 years, or diabetes ≥5 years. GIB was defined by fulfilling all three: hospitalization, red blood cell transfusion, and ICD-10 GIB codes. Because hemoglobin A1c data were unavailable, insulin treatment served as a surrogate for diabetes severity. Kaplan-Meier and Cox proportional hazards models were applied to estimate cumulative incidence and adjusted hazard ratios (aHRs), adjusting for medications and comorbidities. Results: Upper GIB risk increased progressively with diabetes duration: aHR 1.081 (95% confidence interval [CI], 1.008 to 1.159) for IFG; 1.265 (1.128 to 1.418) for new-onset diabetes; 1.561 (1.392 to 1.751) for diabetes <5 years; and 1.738 (1.578 to 1.915) for diabetes ≥5 years. Elevated risk was also observed among those receiving insulin. In contrast, diabetes duration was not significantly related to lower GIB: aHR 0.949 (95% CI, 0.830 to 1.085) for IFG; 1.150 (0.902 to 1.468) for new-onset diabetes; 1.202 (0.944 to 1.531) for diabetes <5 years; and 0.984 (0.792 to 1.224) for diabetes ≥5 years. Conclusions: Longer duration and greater severity of T2DM are associated with increased risk of upper GIB, whereas no significant association was found for lower GIB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.